Search Results - "Arnone, Marc"
-
1
Dabrafenib; preclinical characterization, increased efficacy when combined with trametinib, while BRAF/MEK tool combination reduced skin lesions
Published in PloS one (03-07-2013)“…Mitogen-Activated Protein Kinase (MAPK) pathway activation has been implicated in many types of human cancer. BRAF mutations that constitutively activate MAPK…”
Get full text
Journal Article -
2
Discovery of Dabrafenib: A Selective Inhibitor of Raf Kinases with Antitumor Activity against B‑Raf-Driven Tumors
Published in ACS medicinal chemistry letters (14-03-2013)“…Hyperactive signaling of the MAP kinase pathway resulting from the constitutively active B-RafV600E mutated enzyme has been observed in a number of human…”
Get full text
Journal Article -
3
A Biochemical Rationale for the Anticancer Effects of Hsp90 Inhibitors: Slow, Tight Binding Inhibition by Geldanamycin and Its Analogues
Published in Proceedings of the National Academy of Sciences - PNAS (16-05-2006)“…Heat shock protein (Hsp)90 is emerging as an important therapeutic target for the treatment of cancer. Two analogues of the Hsp90 inhibitor geldanamycin are…”
Get full text
Journal Article -
4
Identification of Peptide Substrates for Human MMP-11 (Stromelysin-3) Using Phage Display
Published in The Journal of biological chemistry (25-07-2003)“…The MMP-11 proteinase, also known as stromelysin-3, probably plays an important role in human cancer because MMP-11 is frequently overexpressed in human tumors…”
Get full text
Journal Article -
5
Development of potent B-RafV600E inhibitors containing an arylsulfonamide headgroup
Published in Bioorganic & medicinal chemistry letters (01-08-2011)“…A potent series of inhibitors against the B-Raf(V600E) kinase have been developed that show excellent activity in cellular assays and good oral bioavailability…”
Get full text
Journal Article -
6
Abstract B88: A selective Raf kinase inhibitor induces cell death and tumor regression of human cancer cell lines encoding B-RafV600E mutation
Published in Molecular cancer therapeutics (10-12-2009)“…Abstract Activation of the Ras-Raf-MEK-ERK pathway has been implicated in a large range of human cancers. Growth factor receptor stimulation by extracellular…”
Get full text
Journal Article -
7
Synthesis and Biological Evaluation of 1-Aryl-4,5-dihydro-1H-pyrazolo[3,4-d]pyrimidin-4-one Inhibitors of Cyclin-Dependent Kinases
Published in Journal of medicinal chemistry (18-11-2004)“…Using a high-throughput screening strategy, a series of 1-aryl-4,5-dihydro-1H-pyrazolo[3,4-d]pyrimidin-4-ones was identified that inhibit the cyclin-dependent…”
Get full text
Journal Article -
8
Putative identification of functional interactions between DNA intercalating agents and topoisomerase II using the V79 in vitro micronucleus assay
Published in Mutation research (19-06-2002)“…Clastogenicity is frequently observed following treatment of mammalian cells with new chemical entities. This clastogenicity, unless proven otherwise, is…”
Get more information
Journal Article -
9
Abstract 5035: Predictions of therapeutic doses of a B-Raf inhibitor, GSK2118436, based on exposure-response modeling of preclinical tumor biomarker and xenograft data
Published in Cancer research (Chicago, Ill.) (15-04-2011)“…Abstract Background: GSK2118436 is a potent inhibitor of B-Raf, a signal transduction kinase in the MAPK pathway that can be mutated to become an oncogenic…”
Get full text
Journal Article -
10
Development of potent B-Raf super(V600E inhibitors containing an arylsulfonamide headgroup)
Published in Bioorganic & medicinal chemistry letters (01-08-2011)“…A potent series of inhibitors against the B-Raf super(V600E kinase have been developed that show excellent activity in cellular assays and good oral…”
Get full text
Journal Article -
11
Development of potent B-Raf V600E inhibitors containing an arylsulfonamide headgroup
Published in Bioorganic & medicinal chemistry letters (2011)“…A potent series of inhibitors against the B-Raf V600E kinase have been developed that show excellent activity in cellular assays and good oral bioavailability…”
Get full text
Journal Article -
12
-
13